<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084548</url>
  </required_header>
  <id_info>
    <org_study_id>FLA 18-088</org_study_id>
    <nct_id>NCT04084548</nct_id>
  </id_info>
  <brief_title>Perioperative Lidocaine and Ketamine in Abdominal Surgery</brief_title>
  <official_title>Lidocaine and Ketamine in Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to test the hypothesis that perioperative infusions of lidocaine
      and/or ketamine reduce opioid consumption and pain scores in adults recovering from elective
      inpatient abdominal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a prospective, randomized, double-blind, placebo-controlled
      clinical trial (RCT) with a factorial design. Adults 18 to 80 years old having elective
      inpatient open or laparoscopic abdominal surgery with general anesthesia lasting 2 hours or
      longer will be included in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Double-blind factorial randomization to lidocaine or placebo and ketamine or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pharmacy-prepared medications.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores</measure>
    <time_frame>First postoperative 48 hours (measured at the end of the PACU stay as well as on the 1st and 2nd postoperative mornings).</time_frame>
    <description>Pain scores based on the visual analog scale and Brief Pain Inventory. Ranges from 0 to 10, with 0 being no pain and 10 being the worst imaginable pain. The intervention will be deemed effective if both outcomes are non-inferior, and at least one is superior, to the control group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total opioid consumption</measure>
    <time_frame>First postoperative 48 hours</time_frame>
    <description>Total opioid consumption in oral morphine equivalents (mg) from the time of transfer to PACU through to the second postoperative morning. The intervention will be deemed effective if both outcomes are non-inferior, and at least one is superior, to the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall benefit of analgesia score (OBAS)</measure>
    <time_frame>First postoperative 48 hours (measured at the end of the PACU stay as well as on the 1st and 2nd postoperative mornings).</time_frame>
    <description>Measures 7 different items, i.e. current pain, vomiting, itching, sweating, freezing, dizziness, and patient satisfaction related to pain management. Each item is scored from 0 to 4, with the total OBAS score ranging from 0 to 28. The lower the total OBAS score, the higher the benefit of analgesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery (QoR-15) score</measure>
    <time_frame>First postoperative 48 hours (measured at the end of the PACU stay as well as on the 1st and 2nd postoperative mornings).</time_frame>
    <description>Measures 15 different items, i.e. ability to breathe easily, enjoy food, feel rested, have a good sleep, look after personal toilet and hygiene unaided, communicate with family or friends, getting support from hospital doctors and nurses, return to work or usual home activities, feel comfortable and in control, have a feeling of general well-being, as well as the presence of moderate pain, severe pain, nausea or vomiting, feeling worried or anxious, and feeling sad or depressed. Each item is scored from 0 to 10, with a total QoR-15 score ranging from 0 to 150. The higher the QoR-15 score, the better the quality of recovery in the postoperative period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to first opioid administration</measure>
    <time_frame>The amount of time from PACU admission to PACU discharge</time_frame>
    <description>Measured in minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative hospital length of stay</measure>
    <time_frame>The number of days from hospital admission to hospital discharge</time_frame>
    <description>Measured in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Nausea or vomiting</measure>
    <time_frame>First postoperative 48 hours</time_frame>
    <description>Measured as dichotomous outcome (yes/no)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine and ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine and ketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine and ketamine</intervention_name>
    <description>Perioperative lidocaine and ketamine infusion (see below for dosages and timings)</description>
    <arm_group_label>Lidocaine and ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)</description>
    <arm_group_label>Lidocaine and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)</description>
    <arm_group_label>Ketamine and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Perioperative placebo infusion (normal saline)</description>
    <arm_group_label>Placebo and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 to 80 years old

          -  Elective inpatient open or laparoscopic abdominal surgery

          -  General anesthesia lasting 2 hours or longer.

        Exclusion Criteria:

          -  1. Planned postoperative mechanical ventilation

          -  2. Planned regional anesthesia/analgesia

          -  3. Perioperative gabapentin, magnesium, or nitrous oxide use

          -  4. Pregnancy or breastfeeding

          -  5. Morbid obesity (BMI ≥ 35 kg/m2)

          -  6. American Society of Anesthesiologists (ASA) physical status IV-V

          -  7. Allergy to study medications

          -  8. Contraindication to lidocaine (severe cardiac arrhythmia)

          -  9. Contraindication to ketamine (psychiatric disorder, substance abuse, uncontrolled
             hypertension, pulmonary hypertension, increased intracranial or intraocular pressure,
             use of monoamine oxidase inhibitors)

          -  10. Chronic preoperative opioid use (≥ 90 morphine mg equivalents per day for &gt; 3
             months)

          -  11. Significant preoperative hepatic dysfunction (alanine aminotransferase or
             aspartate aminotransferase levels &gt; 5 times normal) or planned liver transplantation

          -  12. Preoperative cardiac failure (left ventricular ejection fraction ≤ 40%)

          -  13. Unable to communicate or comprehend study instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Minear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Minear, MD</last_name>
    <phone>954-290-1569</phone>
    <email>minears@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca YS Wong, MBBS, MPH</last_name>
    <phone>954-789-8933</phone>
    <email>wongr3@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Minear, MD</last_name>
      <phone>954-290-1569</phone>
      <email>minears@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca YS Wong, MBBS, MPH</last_name>
      <phone>954-789-8933</phone>
      <email>wongr3@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Y Wong, MBBS, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Luis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel I Sessler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuele Lo Menzo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward J Mascha, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Liang, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Collins, AAB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Jacobs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Jamroz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Plata Aguilar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerges Azer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estelle Swanson, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kindlee Lindsay, ARNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Minear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grady MV, Mascha E, Sessler DI, Kurz A. The effect of perioperative intravenous lidocaine and ketamine on recovery after abdominal hysterectomy. Anesth Analg. 2012 Nov;115(5):1078-84. doi: 10.1213/ANE.0b013e3182662e01. Epub 2012 Sep 25.</citation>
    <PMID>23011561</PMID>
  </reference>
  <reference>
    <citation>Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, Hollmann MW, Poepping DM, Schnabel A, Kranke P. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev. 2018 Jun 4;6:CD009642. doi: 10.1002/14651858.CD009642.pub3. Review.</citation>
    <PMID>29864216</PMID>
  </reference>
  <reference>
    <citation>Elia N, Tramèr MR. Ketamine and postoperative pain--a quantitative systematic review of randomised trials. Pain. 2005 Jan;113(1-2):61-70. Review.</citation>
    <PMID>15621365</PMID>
  </reference>
  <reference>
    <citation>Ye F, Wu Y, Zhou C. Effect of intravenous ketamine for postoperative analgesia in patients undergoing laparoscopic cholecystectomy: A meta-analysis. Medicine (Baltimore). 2017 Dec;96(51):e9147. doi: 10.1097/MD.0000000000009147. Review.</citation>
    <PMID>29390443</PMID>
  </reference>
  <reference>
    <citation>Zhao JB, Li YL, Wang YM, Teng JL, Xia DY, Zhao JS, Li FL. Intravenous lidocaine infusion for pain control after laparoscopic cholecystectomy: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018 Feb;97(5):e9771. doi: 10.1097/MD.0000000000009771.</citation>
    <PMID>29384867</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Li T, Wang N, Yun Y, Gan TJ. Perioperative systemic lidocaine for postoperative analgesia and recovery after abdominal surgery: a meta-analysis of randomized controlled trials. Dis Colon Rectum. 2012 Nov;55(11):1183-94. doi: 10.1097/DCR.0b013e318259bcd8. Erratum in: Dis Colon Rectum. 2013 Feb;52(2):271.</citation>
    <PMID>23044681</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multimodal analgesia</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Abdominal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04084548/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04084548/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

